🔎 Trials Near Me

Home › Kanser sa Baga › Pennsylvania › Harrisburg

Pag-aaral pangklinika para sa Kanser sa Baga sa Harrisburg, PA

9 pag-aaral para sa Kanser sa Baga ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Harrisburg (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Nagre-recruitPhase 3
  • Penn State Milton S Hershey Medical Center, Hershey · 12 mi ang layo
Edad 70 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06096844

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Nagre-recruitPhase 3
  • UPMC Pinnacle Cancer Center/Community Osteopathic Campus, Harrisburg
  • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion, Mechanicsburg · 8 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT04267848

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Nagre-recruitPhase 3
  • UPMC Pinnacle Cancer Center/Community Osteopathic Campus, Harrisburg
  • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion, Mechanicsburg · 8 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06498635

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Nagre-recruitPhase 3
  • Penn State Milton S. Hershey Medical Center, Hershey · 12 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06881784

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Nagre-recruitPhase 3
  • Penn State Milton S. Hershey Medical Center-Penn State Cancer Institute ( Site 0059), Hershey · 12 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06312137

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Nagre-recruitPhase 3
  • Penn State Milton S Hershey Medical Center, Hershey · 12 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT05624996

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Nagre-recruitPhase 2
  • UPMC Pinnacle Cancer Center/Community Osteopathic Campus, Harrisburg
  • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion, Mechanicsburg · 8 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 3, 2026 · NCT05642572

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Nagre-recruitPhase 2/3
  • UPMC Pinnacle Cancer Center/Community Osteopathic Campus, Harrisburg
  • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion, Mechanicsburg · 8 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update May 5, 2026 · NCT06616584

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Nagre-recruitPhase 2
  • Penn State Milton S. Hershey Medical Center, Hershey · 12 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 27, 2025 · NCT03175224

Pag-aaral para sa Kanser sa Baga sa ibang lungsod

Iba pang pag-aaral sa Harrisburg

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.